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osting by EAbstract Metoclopramide hydrochloride (MCP) is commonly used for the management of gastro-
intestinal disorders. Frequent administration and the undesired side effects (extra pyramidal symp-
toms) of the drug on the central nervous system due to the ﬂuctuations of its plasma concentrations
may lead to patient incompliance, and hence, improper therapy. Therefore, the present work will be
devoted to formulate the drug in sustained release formulations. MCP was incorporated in 12 for-
mulae containing different polymers and/or different polymer ratios. These polymers were hydroxy-
propylmethyl cellulose (HPMC), carboxymethylcellulose (CMC) and ethyl cellulose (EC). Sodium
starch glycolate (SSG) was added to some formulae in different amounts in order to soften and/or
disintegrate the tablets. Both direct compression and granulation techniques were used to prepare
the tablets. The physical properties were found to be satisfactory for all the formulae. The dissolu-
tion proﬁles of the tablets were constructed using the change-over method. The drug release
involved a combination of both diffusion and polymer-chain relaxation mechanisms. The time
required to release 50% of MCP ranged from 1.2 to more than 8 h. Direct compression and dry
granulation techniques produced sufﬁcient sustaining of the drug release. However, the pellets made
by wet granulation released MCP in about 2 h, i.e., pelletization spheronization technique was not
effective in sustaining the drug.
ª 2009 King Saud University. All rights reserved.. Abdel-Rahman).
ity. All rights reserved. Peer-
d University.
lsevier1. Introduction
Metoclopramide hydrochloride (MCP) is a freely soluble drug
and is rapidly absorbed from the gastrointestinal tract (GIT)
(Martindale, 1993). It has a relatively short variable biological
half life (5 ± 1 h) and is usually administered in a peroral dose
of 10–15 mg four times daily, as immediate release tablets. The
blood level ﬂuctuation resulting from this frequent administra-
tion leads to extrapyramidal symptoms (USP DI, 1998).
The relatively small daily dose, short half life, undesirable
side effects and rapid absorption from the GIT make MCP a
good candidate for formulation in a sustained release dosage
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et al., 2002) may discourage the sustaining of its release. How-
ever, it has been found that, this metabolism is linear as re-
vealed by the bioequivalence of a sustained release dosage
form with a solution of MCP (Beckett et al., 1987). This
linearity does not hinder the formulation of MCP in sustained
release dosage form. Such sustaining of the drug release would
obviate the secondary effects of the drug on the central ner-
vous system normally encountered with the administration of
immediate release formulations. This, together with decreasing
the frequency of administration, would improve the patient
compliance.
Because of low costs and ease of fabrication, one of the most
common approaches to get controlled release is to embed a drug
in a hydrophobic matrix such as Eudragit and ethylcellulose
(Lotiﬁpour et al., 2004) or hydrophilic matrix such as hydroxy-
propylcellulose, hydroxypropylmethylcellulose, methylcellulose,
sodium carboxymethylcellulose, alginates and scleroglucan
(Hasan et al., 2003; Winterowd and Sandford, 1995; Moe
et al., 1995). Dispersing the drug in cross linked chitosan, spray
dried microspheres of hydrogel-forming polymers, hydrophilic
polymers and alginates have been reported in the literature to
sustain MCP release (Ganza-Gonzalez et al., 1999).
In the present study, MCP was formulated in matrix tablets
and pellets using varying proportions of the cellulosic poly-
mers HPMC, CMC and EC. A super disintegrant (SSG) was
employed to produce softer and/or disintegrating tablets as a
desired property for matrix tablets to avoid failure of release.
Moreover, the inﬂuence of the technique used, namely, direct
compression, dry granulation and pelletization spheronization
on tablets and pellets properties was investigated. The physical
properties of the tablets and the release proﬁles from tablets
and pellets and their relevant kinetics were determined.
2. Materials
Metoclopramide (MCP) was generously obtained from Egyp-
tian Pharmaceutical International Company (EPICO), Egypt.
Carboxymethyl cellulose sodium (CMC), high viscosity grade,
and sodium starch glycolate (SSG) were purchased from BDH
Co, Poole, England. Hydrxypropylmethyl cellulose (HPMC
K4M) was purchased from Dow Chemical Company, Mid-
land, Michigan, USA. Ethyl cellulose (EC) was obtained from
ICN Biomedicals, Inc, Ohio, USA. Avecil PH102 was ob-
tained from Serva GmbH & Co., Heidelberg, Germany.Table 1 Formulae of metoclopramide tablets made by different me
Composition (mgs) of the prepared formulation
F1 F2 F3 F4 F5
MCP 30 30 30 30 30
HPMC 90 70 90 30 90
CMC 50 – 30 90 30
SSG – – – – 20
Avecil 30 50 50 50 30
Mag stearate 2 2 2 2 2
EC – 50 – – –
Methoda DC DC DC DC DC
Tablet weight (mg) 202 202 202 202 202
a DC, DG, PS designate direct compression, dry granulation and pelle3. Methods
3.1. Preparation of tablets by the direct compression technique
Components of each formula as shown in Table 1 were mixed
in turbula mixer (type S27, Erweka, Apparatebau, Germany)
for 15 min and then directly compressed into tablets using a
single punch tablet machine (type EKO, Erweka, Apparate-
bau, Germany) using 10 mm ﬂat punches. Tablets hardness
was kept within the range of 5–8 kp.
3.2. Preparation of tablets by the dry granulation technique
Components of each formula as shown in Table 1 were mixed in
turbula mixer (type S27, Erweka, Apparatebau, Germany) for
5 min and then compressed using a single punch tablet machine
(type EKO, Erweka, Apparatebau, Germany), using 12 mm ﬂat
punches. The produced slugs were then crushed into dry gran-
ules and passed through sieve size 800 lm and retained on sieve
size 250 lm. The rest of disintegrant and lubricant (one half
amount of each) were added, mixed in turbula mixer for
3 min, and then compressed by a single punch tablet machine,
(type EKO, Erweka, Apparatebau, Germany) using 10 mm ﬂat
punches. Tablet hardness was kept within the range of 5–8 kp.
3.3. Preparation of pellets
Components of formula10 as shown in Table 1 were milled,
and mixed in mortar. Water was gradually added to the pow-
der mixture with trituration until the formation of coherent
mass. The resulting wet mass was extruded at a speed of
85 rpm (Mini Screw Extruder, Model MSE1014, Caleva, Eng-
land), through 1 mm diameter die. Spheronization was per-
formed in a spheronizer (Model 120, Caleva, England) with
a rotating plate of regular cross-hatch geometry, at a speed
of 500–600 rpm, for 10 min. Pellets were then dried on a tray
in an hot oven at 50 C for 12 h.
3.4. Tablet evaluation
Hardness of 10 tablets were measured using hardness tester
(type TBH28, Erweka, Apparatebau, Germany) and the mean
was listed in Table 2, friability of 20 tablets were measured
using friability tester (type TA3R, Erweka, Apparatebau, Ger-
many) and the mean was listed in Table 2. Weight uniformitythods and the physical properties of the produced tablets.
s
F6 F7 F8 F9 F10 F11 F12
30 30 30 30 30 30 30
70 70 80 90 80 70 80
30 50 30 30 30 30 30
20 20 30 10 30 40 30
50 30 30 40 30 30 30
2 2 2 2 2 2 2
– – – – – – –
DC DC DC DC DG DG PS
202 202 202 202 202 202 –
tization spheronization, respectively.
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Figure 1 Dissolution proﬁles of MCP tablets in 0.1 N HCl (pH
1.2) and phosphate buffer (pH 6.8) at 37 ± 0.5 C.
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Figure 2 Dissolution proﬁles of MCP tablets in 0.1 N HCl (pH
1.2) and phosphate buffer (pH 6.8) at 37 ± 0.5 C.
Table 2 Physical properties of metoclopramide tablets made by different methods.
Formula no. Methoda Weight uniformity: Average tablet weight
(mg ± SD)
Hardness (kp)
mean ± SD
Friability
(%)
1 DC 203 ± 1.5 7.2 ± 0.40 0.51
2 DC 204 ± 1.6 5.8 ± 0.30 0.42
3 DC 203 ± 1.4 6.3 ± 0.31 0.48
4 DC 202 ± 1.6 6.1 ± 0.32 0.46
5 DC 203 ± 1.4 6.5 ± 0.29 0.42
6 DC 202 ± 1.6 5.9 ± 0.30 0.51
7 DC 205 ± 1.6 6.2 ± 0.32 0.43
8 DC 203 ± 1.4 6.0 ± 0.29 0.44
9 DC 204 ± 1.4 6.1 ± 0.32 0.42
10 DG 202 ± 1.3 7.5 ± 0.41 0.40
11 DG 203 ± 1.4 7.3 ± 0.40 0.39
a DC, DG designate direct compression and dry granulation, respectively.
Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets 285test of 20 tablets was carried out according to BP limits and the
results were listed in Table 2.
3.5. In vitro release studies
The dissolution runs were carried out by the change-over
methods originally used in the USP for enteric coated tablets
(USP DI, 1998). In each of the ﬂasks of the USP apparatus
1 (Caleva Ltd., Model 85T) 750 ml of 0.1 N HCl (pH 1.2) were
equilibrated to 37 ± 0.5 C at 50 rpm using a continuous auto-
mated monitoring system. This system consists of an IBM
computer PK8620 series and PU 8605/60 dissolution test soft-
ware, Philips VIS/UV/NIR single beam eight-cell spectropho-
tometer Model PU 8620, Epson FX 850 printer, and Watson–
Marlow peristaltic pump. An accurately weighed tablet of each
of the prepared formulations was added to each ﬂask. Samples
were withdrawn at time intervals for 2 h, and then the pH was
changed to 6.8 by adding 250 ml of 0.2 M trisodium phos-
phate. For each formula, release runs were performed in trip-
licate and absorbance was recorded automatically at 309 nm
up to 8 h. The cumulative percentage of drug released was
determined as a function of time.
3.6. Statistical analysis
The results were analyzed by using the software graph pad
prism5 applying one-way ANOVA. Differences between for-
mulations were considered to be signiﬁcant at p 6 0.05.
4. Results and discussion
The MCP controlled release matrix tablets were prepared
using different techniques and different polymers. As shown
in Table 1, the tablets gave satisfactory physical properties
concerning the hardness and friability. The values of the latter
lay quite below the USP maximum limits. The weight unifor-
mity of the tablets was within the BP limits, Table 2.
4.1. Dissolution proﬁles of MCP from different polymer
matrices
As shown in Figs. 1–3, the steepest part for all the dissolution
curves is the ﬁrst 2-h-segment which represents the MCP disso-
lution in the acid medium. This relatively fast dissolution ratemay be attributed to the relatively low viscosity of celluloseic
polymers at acidic pH which enhances the acid penetration
into the matrix tablet, and hence, increasing MCP release.
On raising the pH from 1.2 to 6.8, the penetrability of the dis-
solution medium decreases leading to slower drug release.
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Figure 3 Dissolution proﬁles of MCP tablets and pellets in 0.1 N
HCl pH (1.2) and phosphate buffer (pH 6.8) at 37 ± 0.5 C.
Table 3 T50% and T75% for different formulations.
Formula no. T50% (h)a T75% (h)a
F1 2.2 5.44
F2 1.24 3.20
F3 >8 >8
F4 2.44 3.76
F5 2.24 5.28
F6 1.84 4.32
F7 2.64 6.36
F8 2.76 6.32
F9 2.80 6.48
F10 4.40 >8
F11 2.48 5.8
F12 0.28 0.5
a T50% and T75% (the time required for 50% and 75% drug to
be released).
286 S.I. Abdel-Rahman et al.Figs. 1–3 and Table 3 reveal that MCP release was the fast-
est from F12 (pellets) and the slowest from F3 made by direct
compression and contains relatively high proportion of HPMC
in absence of the disintegrant SSG. Replacing the hydrophilicTable 4 Kinetic modeling of MCP release from different formulati
Formula no. Zero order model First order
r Ko r
F1 0.942 9.53 0.942
F2 0.940 11.39 0.970
F3 0.961 3.95 0.970
F4 0.963 12.31 0.980
F5 0.978 10.18 0.990
F6 0.968 10.35 0.991
F7 0.953 9.21 0.990
F8 0.954 9.51 0.992
F9 0.959 7.38 0.990
F10 0.966 7.38 0.980
F11 0.967 9.66 0.980
r= correlation coefﬁcient, Ko is the zero order release rate constant (mg%
coefﬁcient (mg%/h½), and n is the release exponent.polymer CMC in F1 by the hydrophobic polymer EC (F2) re-
sulted in a signiﬁcant increase in MCP release (p< 0.05) com-
pared with F1, Table 4. This could be due to the effect of EC
on the compressibility of the tablet matrix as reﬂected by the
lower hardness value, Table 2. Comparing the values of
T50% and T75% (time for 50% and 75% drug to be released)
for the Formulae F3, F5 and F9 having the same composition
except for SSG and made by the same technique (direct com-
pression) reveals that the absence of SSG (F3) has drastically
sustained the release (Fig. 4). Despite F5 contains double the
amount of SSG present in F9, the release from F5 was non sig-
niﬁcantly increased (p> 0.05) as shown by the release rates in
Table 4. This may indicate that increasing SSG above 10%
would not affect anymore the release of MCP. However, it
was visually observed that as the percentage of SSG in the for-
mula is increased the tablet erosion in the dissolution medium
was more apparent. For matrix tablets, more erosion is prefer-
able (keeping the sustaining of release) because it may be help-
ful in avoiding release failure. If SSG helps the matrix tablet to
disintegrate into granules under the hydro-dynamic conditions
of the stomach, the tablet would gain the known advantages of
a multi-unit dosage form (e.g. microcapsules or microspheres)
including the ease of granule transfer to the intestine regardless
of food content of the stomach (Gibaldi et al., 1991).
The effect of HPMC/CMC ratio on MCP release is repre-
sented by Formulae F3, F4. Fig. 1 and Tables 3 and 4 show
that when the ratio was 3:1 (F3) a pronounced slowing of re-
lease was observed. On reversing this ratio (F4), the rate of
MCP release was 10-fold increased. This may be attributed
to the effect of pH on the viscosity of CMC which is less ion-
ized in acidic medium, and hence less viscous.
The effect of the method of preparation of the tablets and
pellets is represented by F8, F10 and F12 as shown in Tables
3 and 4 and Fig. 5. Despite these three formulae have the same
composition, the release is more sustained by using the dry
granulation method, F10. This may be interpreted by the fact
that in this method the ingredients have been subjected twice
for compression. The inﬂuence of this excessive compression
is also reﬂected in the higher hardness value of F10 compared
to that of F8. The release from pellets, F12, was the highest as
shown in Table 3, and Fig. 5 compared to the tablets having
the same composition. This is due to the higher surface areaons.
model Higuchi diﬀusion
model
n-value
K1 r D
0.23 0.996 0.931 0.712
1.54 0.994 1.39 0.738
0.046 0.992 0.136 0.583
0.46 0.988 1.31 0.758
0.21 0.989 0.87 0.722
0.23 0.990 0.92 0.725
0.184 0.993 0.78 0.720
0.184 0.992 0.825 0.728
0.185 0.959 0.78 0.720
0.07 0.998 0.491 0.671
1.25 0.997 0.838 0.712
/h), K1 is the ﬁrst order release rate constant (h
1), D is the diffusion
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Figure 4 Effect of disintegrant (SSG) amount on metoclopra-
mide release. (F3: no SSG, F5: 5% SSG, F9: 10% SSG).
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Figure 5 Effect of method of preparation on metoclopramide
release. (F8: DC, F10: DG, F12: PS).
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that the pelletization method gave too hard pellets that were
incompressible.
Both F10 and F11 were made by dry granulation. The re-
lease from F11 is quicker than that from F10, Tables 3 and
4 and Fig. 3, because of decreased weight of HPMC and in-
creased weight of SSG in the latter formula. F9 contains more
HPMC and less SSG compared to F11. However, the release
of MCP is almost the same from either formulae, Fig. 3 and
Table 3. This means that the dry granulation method used
for F11 has cancelled the effect of decreasing of HPMC and
increasing of SSG amounts in sustaining the drug release.
In general, Formulae 7–11 were successful in sustaining
MCP release since T75% ranged from 5.8 to >8 h, Table 3.
However, Formulae 3 and 10 have excessively retarded the
drug release. Formulae F2 and F12 have released MPC too
fast; T75% was 3.2 and 0.5 h, respectively.
4.2. Kinetic assessment of the in vitro release of MCP from the
prepared tablets and pellets
In order to determine the release model which best describes
the pattern of drug release, the in vitro release data were ﬁttedto zero order, ﬁrst order and diffusion controlled release mech-
anisms according to the simpliﬁed Higuchi model (Higuchi,
1963).
The preference of a certain mechanism was based on the
correlation coefﬁcient (r) for the parameters studied, where
the highest correlation coefﬁcient is preferred for the selection
of mechanism of release. Successive evidence of the relative
validity of diffusion and ﬁrst order models obtained by analyz-
ing the data using the following equation of Korsmeyer and
Peppas (1983)
Mt=M1 ¼ K  tn;
where Mt/M1 is the fraction released by the drug at time t, K
is a constant incorporating structural and geometric character-
istic and n is the release exponent characteristic for the drug
transport mechanism. When n= 0.5 ﬁckian diffusion is ob-
served and the release rate in dependent on t, while
0.5 < n< 1.0 indicate anomalous (non-ﬁckian) transport
and when n= 1, the release is zero order.
In swellable systems, factors affecting the release kinetics
are liquid diffusion rate and polymeric chain relaxation rate.
When the liquid diffusion is slower than the relaxation rate
of the polymeric chains, the diffusion is Fickian, whereas when
the relaxation process is very slow compared with the diffusion
rate, the case II transport occurs. When liquid diffusion rate
and polymer relaxation rate are of the same order of magni-
tude, anomalous or non-ﬁckian diffusion is observed (Kors-
meyer and Peppas, 1983).
The value of n as estimated by linear regression of logMt/
M1 vis log t of different formulations are shown in table
(Beckett et al., 1987), the obtained values of n ranges between
0.583 and 0.758 for MCP release for all the prepared tablets
which indicates drug release mechanisms involving a combina-
tion of both diffusion and chain relaxation mechanisms.
Therefore, the release of MCP from the prepared tablets is
controlled by the swelling of the polymer followed by drug
diffusion through the swelled polymer and slow erosion of
the tablet. On the other hand, Pellets did not show disintegra-
tion but slight swelling and erosion during the dissolution test,
the authors concluded that MCP release form pellets was
mainly a polymer controlled diffusion and surface erosion
process. This is in accordance with a previously published data
(Mehata et al., 2001). The higher release rate of pellets is due to
higher surface area of pellets and high water solubility of the
drug.
5. Conclusions
Sustained release matrix tablets of metoclopramide hydrochlo-
ride were prepared using different ratios of hydroxypropylm-
ethylcellulose and sodium carboxymethylcellulose. Direct
compression, dry granulation and pelletiazation techniques
were employed to prepare the tablets. The comparative meto-
clopramide release studies revealed that the release rate was
dependent on the polymers relative amounts, the technique
used to prepare the tablets, and the absence or presence of
the super disintegrant sodium starch glycolate. The tablets
made by direct compression and dry granulation were found
to satisfy the compendial requirements of hardness and friabil-
ity. Pellets were incompressible due to their excessive hardness
on drying and were the weakest in sustaining the release. Most
of the formulae prepared by direct compression and dry
288 S.I. Abdel-Rahman et al.granulation have satisfactory sustained the drug release with
the later being more effective. The drug release for all the pre-
pared tablets has shown mechanisms involving a combination
of both diffusion and chain relaxation. Future studies will be
conducted to evaluate these matrix tablets in vivo in the case
of developing a sustained release dosage form of the drug for
better therapy and more patient compliance.Acknowledgments
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